CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
Bevacizumab in combination with standard chemotherapy (CT) in 1st line metastatic colorectal cancer (mCRC) settings prolongs median overall survival to 20,3 months. Data of observational cohort programs suggests that bevacizumab therapy beyond disease progression, in combination with several CT regi...
| Autors principals: | , |
|---|---|
| Format: | Article |
| Idioma: | Russian |
| Publicat: |
“ABV-press” Publishing house”, LLC
2015-02-01
|
| Col·lecció: | Тазовая хирургия и онкология |
| Matèries: | |
| Accés en línia: | https://ok.abvpress.ru/jour/article/view/33 |